PMID- 27466703
OWN - NLM
STAT- MEDLINE
DCOM- 20170310
LR  - 20220408
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 17
IP  - 14
DP  - 2016 Oct
TI  - Omarigliptin for the treatment of type 2 diabetes mellitus.
PG  - 1947-52
LID - 10.1080/14656566.2016.1218472 [doi]
AB  - INTRODUCTION: The estimated global prevalence of diabetes mellitus for adults 
      aged 20-70 in 2015 was 415 million with approximately 90% of diagnosed cases 
      being Type 2 diabetes mellitus (T2DM). Improvements in lifestyle and effective 
      therapies are key to management but due to the progressive nature of T2DM, 
      pharmacotherapy is typically required. Whilst the initial therapy will usually be 
      with metformin, thereafter treatment should be individualised, with consideration 
      of several different second line options. These include the dipeptidyl 
      peptidase-4 (DPP-4) inhibitors, of which omarigliptin is the second once weekly 
      version. AREAS COVERED: The paper summarises key pharmoacodynamic and 
      pharmacokinetic features and reviews the efficacy and safety trial data of 
      omarigliptin, a once-weekly DPP-4 inhibitor. EXPERT OPINION: Omarigliptin results 
      in a significant improvement in glycaemia with an effective once weekly 
      pharmacokinetic profile and low risk of drug-drug interactions. It has equivalent 
      efficacy to existing once daily DPP-4 inhibitors and shares a similar side effect 
      profile. It is weight neutral with a significantly lower risk of hypoglycaemia 
      compared with sulphonylureas. Adherence to prescribed medication is poor in 
      patients with T2DM. Once weekly omarigliptin is a welcomed addition to the 
      therapeutic armoury but whether it will improve compliance remains to be seen.
FAU - Evans, Philip M S
AU  - Evans PM
AD  - a Royal Glamorgan Hospital , Llantrisant , Wales, UK.
FAU - Bain, Stephen C
AU  - Bain SC
AD  - b Diabetes Research Unit Cymru , Swansea University , Swansea , Wales , UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 
      (2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4H)-yl)tetrahydro-2H-pyran-3-amine)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Heterocyclic Compounds, 2-Ring)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Pyrans)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/drug effects
MH  - Body Weight
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Drug Interactions
MH  - Heterocyclic Compounds, 2-Ring/*therapeutic use
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/therapeutic use
MH  - Middle Aged
MH  - Pyrans/*therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - compliance
OT  - dipeptidyl peptidase-4 (DPP-4) inhibitor
OT  - omarigliptin
EDAT- 2016/07/29 06:00
MHDA- 2017/03/11 06:00
CRDT- 2016/07/29 06:00
PHST- 2016/07/29 06:00 [entrez]
PHST- 2016/07/29 06:00 [pubmed]
PHST- 2017/03/11 06:00 [medline]
AID - 10.1080/14656566.2016.1218472 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2016 Oct;17(14):1947-52. doi: 
      10.1080/14656566.2016.1218472.